On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Stocktwits on MSN13h
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback